Similarly, in the p53/Myc pathway, disrupting the Runx consensus site mR1 in the Myc promoter or impairing Runx3 reduces Myc expression, effectively decreasing tumorigenicity in p53-deficient osteosarcoma cells. The gene discussed is MYC; the disease is osteosarcoma.